Skip to main content
AmigoFish

ESMO 2026 GU Highlights VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011

From Oncology Brothers: Practice-Changing Cancer Discussions · · 21 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Drs. Shilpa Gupta and Ashish Kamat, to discuss the latest updates from ESMO 2026 in Madrid. With nearly 40,000 attendees and thousands of abstracts presented, we focus on the most impactful findings in genitourinary (GU) oncology.

Episode Highlights:

- Muscle-Invasive Bladder Cancer (MIBC): A deep dive into the VOLGA trial, exploring the efficacy of neoadjuvant therapy with durvalumab and enfortumab vedotin (EV) in MIBC. We discussed the implications of reduced toxicity and potential changes to standard care.

- Non-Muscle-Invasive Bladder Cancer (NMIBC): Insights from the POTOMAC update and the role of durvalumab in high-risk, BCG-naive patients.

- Prostate Cancer: An overview of the DASL-HiCaP and PROTEUS studies, highlighting the use of androgen receptor pathway inhibitors (ARPIs) in earlier lines of treatment and their impact on metastasis-free survival (MFS).

- Renal Cell Carcinoma (RCC): Updates on KEYNOTE-564 and the LITESPARK studies, focusing on adjuvant therapies and the balance between efficacy and side effects.

Join us as we cut through the noise and focus on what is practice-changing in the field of oncology.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

- ⁠X/Twitter: https://x.com/oncbrothers

- Instagram: https://www.instagram.com/oncbrothers

- Website: https://oncbrothers.com/

Don't forget to subscribe for more insights and updates from the world of cancer research!

#ESMO2026, #GUOncology, #BladderCancer, #ProstateCancer, #KidneyCancer, #OncologyBrothers

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem